ANI Pharmaceuticals (ANIP) said Monday it has launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg doses.
The product is a generic version of Carbatrol and targets a US market with annual sales of about $65 million, the company said, citing IQVIA data.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.